Loading…
Regeneron Pharmaceuticals, Inc. is projected to rise to $717.37 by 2027, a +8% move from its current price of $664.52. REGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $654.28 | $664.85 | $675.59 | +0.05% |
| Jul 15 | $650.27 | $665.18 | $680.42 | +0.10% |
| Jul 16 | $647.29 | $665.51 | $684.23 | +0.15% |
| Jul 17 | $644.84 | $665.83 | $687.52 | +0.20% |
| Jul 18 | $642.72 | $666.16 | $690.46 | +0.25% |
| Jul 19 | $640.84 | $666.49 | $693.17 | +0.30% |
| Jul 20 | $639.14 | $666.82 | $695.70 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $639.14 | $666.82 | $695.70 | +0.35% |
| Week 2 | $630.19 | $669.13 | $710.47 | +0.69% |
| Week 3 | $623.91 | $671.45 | $722.60 | +1.04% |
| Week 4 | $619.00 | $673.77 | $733.39 | +1.39% |
| Week 5 | $614.96 | $676.11 | $743.33 | +1.74% |
| Week 6 | $611.53 | $678.45 | $752.68 | +2.10% |
| Week 7 | $608.57 | $680.80 | $761.60 | +2.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc.
to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies.
It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc. (REGN) is a member of the Healthcare sector with a current price of $676.23 per share and a market cap of $70.9B. It is ranked 238 by market capitalization. The stock sits near the mid-$600s, reflecting a sizable but steady market presence.
A major floor 14.0% below — a decisive break under it would weaken the trend.
The nearest floor, 9.6% below — buyers have tended to step in here.
Price is pressing into resistance (1.8% away) — a breakout level to watch.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key REGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of REGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $664.28 | Buy | $661.31 | Buy |
| MA 10 | $648.86 | Buy | $651.57 | Buy |
| MA 20 | $631.70 | Buy | $642.40 | Buy |
| MA 50 | $649.16 | Buy | $656.01 | Buy |
| MA 100 | $705.11 | Sell | $679.70 | Sell |
| MA 200 | $701.77 | Sell | $688.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.30 | Neutral |
| Stoch RSI (14) | 75.54 | Neutral |
| CCI (20) | 117.14 | Buy |
| Williams %R (14) | -18.37 | Info |
| MACD (12,26,9) | 7.48 | Buy |
| ROC (12) | 7.52 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 81.63 | Sell |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | 36.93 | Buy |
| Ultimate (7,14,28) | 71.90 | Sell |
| Momentum (10) | 44.38 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 675.63 | Sell |
| ADX (14) | 19.65 | Neutral |
| ATR (14) | 9.07 | Info |
The 30-day technical picture is bullish with momentum intact. The RSI(14) sits at 70, and the near-term moving averages show the stock trading above a 50-day moving average of $653.81 while approaching the 200-day moving average at $700.73. Support is noted at $600.66 and resistance at $676.23.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $600.66 | $664.52 | $863.92 | 0% | Neutral | |
| $587.57 | $717.37 | $915.66 | +8% | Neutral | |
| $616.40 | $766.72 | $1,005.15 | +15% | Neutral | |
| $666.98 | $842.44 | $1,127.95 | +27% | Bullish | |
| $770.11 | $985.85 | $1,343.75 | +48% | Bullish | |
| $835.47 | $1,082.58 | $1,498.93 | +63% | Bullish | |
| $856.34 | $1,122.16 | $1,575.86 | +69% | Bullish | |
| $912.31 | $1,208.10 | $1,718.51 | +82% | Bullish | |
| $908.24 | $1,214.68 | $1,748.52 | +83% | Bullish | |
| $948.14 | $1,280.05 | $1,863.13 | +93% | Bullish | |
| $1,250.15 | $1,760.35 | $2,685.11 | +165% | Bullish | |
| $2,428.77 | $3,667.92 | $5,997.23 | +452% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $600.66 | $664.52 | $781.35 | +0.00% |
| August 2026 | $574.14 | $671.90 | $803.22 | +1.11% |
| September 2026 | $591.12 | $695.13 | $837.54 | +3.46% |
| October 2026 | $591.88 | $698.90 | $847.69 | +0.54% |
| November 2026 | $584.78 | $692.93 | $845.11 | -0.85% |
| December 2026 | $592.83 | $704.75 | $863.92 | +1.71% |
Click any year to see its month-by-month REGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The REGN price prediction for 2026 points to an average of $664.52 (low $600.66, high $863.92) — a potential gain of 0% on today's $664.52. A consolidation phase looks the most probable path here.
In 2027, REGN is projected to trade between $587.57 and $915.66, averaging $717.37 — a potential gain of +8% from today's $664.52. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
Regeneron Pharmaceuticals, Inc.'s 2028 outlook centres on $766.72, within a $616.40 to $1,005.15 range. That is up +7% on the projected 2027 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, REGN could reach as high as $1,127.95, with a base case around $842.44 and support toward $666.98 — roughly +27% from $664.52. Momentum favours further upside here.
Expect REGN to range from $770.11 to $1,343.75 through 2030. The $985.85 average target implies a +48% move from current prices. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The REGN price prediction for 2031 points to an average of $1,082.58 (low $835.47, high $1,498.93) — a potential gain of +63% on today's $664.52. Momentum favours further upside here.
In 2032, REGN is projected to trade between $856.34 and $1,575.86, averaging $1,122.16 — a potential gain of +69% from today's $664.52. That is up +4% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Regeneron Pharmaceuticals, Inc.'s 2033 outlook centres on $1,208.10, within a $912.31 to $1,718.51 range. That is up +8% on the projected 2032 average. That marks a +82% change versus current levels. Momentum favours further upside here.
By 2034, REGN could reach as high as $1,748.52, with a base case around $1,214.68 and support toward $908.24 — roughly +83% from $664.52. Buyers look set to stay in control over this stretch.
Expect REGN to range from $948.14 to $1,863.13 through 2035. The $1,280.05 average target implies a +93% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The REGN price prediction for 2040 points to an average of $1,760.35 (low $1,250.15, high $2,685.11) — a potential gain of +165% on today's $664.52. Buyers look set to stay in control over this stretch.
In 2050, REGN is projected to trade between $2,428.77 and $5,997.23, averaging $3,667.92 — a potential gain of +452% from today's $664.52. That is up +108% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in REGN today (≈ 1.504846 REGN) could be worth
$5,519.65
+$4,519.65 (+452%) by 2050 · US Dollar
Based on the average projected REGN price of $3,667.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in REGNwould be worth at today's price.
$1,000 invested in REGN on Jul 10, 2025 (≈ 1.78648 REGN) would be worth
$1,187.15
+$187.15 (+18.7%) today · 1.19× · US Dollar
Based on a REGN entry price of $559.76 vs. today's $664.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $654.27 | $1,015.67 | +1.6% |
| 1 month ago | $601.65 | $1,104.5 | +10.4% |
| 3 months ago | $748.87 | $887.36 | -11.3% |
| 6 months ago | $768 | $865.26 | -13.5% |
| 1 year ago | $559.76 | $1,187.15 | +18.7% |
| All time (5.0y) ago | $581.06 | $1,143.63 | +14.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our REGN forecast.
Our base-case forecast reaches $1,300.00 around 2040.
Implied market cap at $1,300.00: $133.93B
Longer-term forecasts point to a rising price path with substantial upside. The 2026 forecast shows an average price of $676.23 and a maximum of $884.84 (min $600.66), with a 0% ROI. By 2030 the average is $1,017.93 (min $795.03, max $1,387.79) and ROI is 50.5%.
The trajectory continues to 2040 with an average of $1,851.59 (min $1,314.81, max $2,824.60) and ROI of 173.8%. By 2050 the average is $3,879.92 (min $2,568.93, max $6,344.38) and ROI reaches 473.8%. Throughout the period, the sentiment remains BULLISH for the longer horizon, reflecting a strong upside in the modeled path.
Tap a question to reveal the answer.
The forecast shows an average price of $1,017.93, with a min of $795.03 and a max of $1,387.79; ROI 50.5% and sentiment BULLISH.
The long-term outlook shows a bullish trajectory with the average price rising to $3,879.92 by 2050 (max $6,344.38) and ROI of 473.8%, though early years include neutral readings (e.g., 2026 and 2027–2028) and are not guarantees.
Yes. The 2030 forecast lists an average price of $1,017.93 (min $795.03, max $1,387.79), which crosses $1,000 on average.
The 30-day range is from $604.65 to $756.29.
Current price is $676.23 and market cap is $70.9B; the stock is ranked 238.
Regeneron Pharmaceuticals, Inc. Community Discussion
0Share your Regeneron Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.